91 results about "A hemoglobin" patented technology

The invention discloses a hemoglobin-resistant Taq DNA polymerase mutant and a construction method thereof, and relates to the field of biology, and the hemoglobin-resistant Taq DNA polymerase mutant is characterized in that a nucleotide sequence for coding the Taq DNA polymerase is shown as SEQ ID NO.1, and the mutant comprises at least one mutation or all mutations selected from S623D and E721A sites. On the basis of natural Taq DNA polymerase, the molecular structure of the Taq DNA polymerase is modified through rational design and combination with a site-specific mutagenesis biotechnology, so that the Taq DNA polymerase mutant is more suitable for PCR amplification of samples containing hemoglobin and the like than a wild type, and the result judgment accuracy of a sample containing a hemoglobin inhibitor is more facilitated.

The invention belongs to the field of biological medicine, and provides a protection liquid capable of preserving in-vitro animal organs or in-vitro animal tissues at normal temperature as well as a preparation method and application of the protection liquid, and the protection liquid comprises a solution containing a hemoglobin oxygen carrier or a hemoglobin carrier, an osmotic pressure regulating substance and the like. The protective liquid provided by the invention can be used for preserving or perfusing broken limbs, isolated animal organs or isolated animal tissues at normal temperature, and can also be used as a culture liquid of artificial organs and artificial tissues.

The invention belongs to the technical field of medical treatment, and particularly relates to a hemoglobin chyle joint detection device and a detection method.The hemoglobin chyle joint detection device comprises a shell, an analysis mechanism is arranged in the shell, and a colorimetric tube is inserted into the upper surface of the shell; the analysis mechanism comprises a light source module, a sample processing module, an optical detection module and a data processing module; the optical detection module synchronously acquires absorbance signals under two wavelengths through double detectors; the data processing module calculates hemoglobin concentration and chyle degree based on the dual wavelength absorbance values. The method is different from traditional single-index detection, two-parameter synchronous analysis of hemoglobin and chyle is achieved for the first time, and the preliminary screening efficiency before blood donation is remarkably improved. By adopting a dual-wavelength correction algorithm, the influence of residual absorption interference of hemoglobin at 580-700nm on chyle index determination is eliminated, and the influence of absorption interference of chyle at 480-570nm on hemoglobin determination is eliminated. The method is suitable for rapid screening on a blood sampling site to realize informatization management of detection data.

The invention relates to a continuous noninvasive physiological parameter detection method and device, and belongs to the technical field of physiological parameter detection. According to the method, on the basis of photoelectric volume pulse wave detection data under multiple wavelengths, absorbance related characteristic parameters and pulse wave related characteristic parameters are extracted, a hemoglobin concentration detection result is obtained through calculation of a hemoglobin concentration calculation model, and the absorbance related characteristic parameters comprise the adjacent surface difference, the relative difference, the adjacent surface ratio, the relative ratio and the progressive surface ratio. Extracting based on a normalized absorbance fluctuation amplitude curve; the pulse wave characteristic parameters comprise rising branch maximum slope, rising time, falling time, dicrotic wave slope, dicrotic amplitude ratio, rising branch time ratio, low-high frequency energy ratio and harmonic component ratio, and extraction is carried out based on normalized pulse waves. The detection device for implementing the method comprises a probe, a data processing circuit and the like. The accuracy of the noninvasive hemoglobin concentration detection result can be effectively improved.

The invention relates to a hemoglobin peptide capable of promoting iron absorption and a preparation method thereof, the mass content of polypeptide in the hemoglobin peptide is greater than 90%, and the hemoglobin peptide contains at least one of FERF and FDGL; the preparation method comprises the following steps: S1, adding trisodium citrate into fresh animal blood, centrifuging, adding a NaCl solution for washing, preparing the solution, and performing high-pressure homogenization wall breaking for 2-5 times to obtain a hemoglobin solution; s2, adding 10-200 U / mL of neutral protease, carrying out heat preservation treatment, then adding 5-50 U / mL of flavourzyme, carrying out enzymolysis, and carrying out enzyme deactivation to obtain an enzymatic hydrolysate; s3, filtering with an ultrafiltration membrane, and collecting permeate; s4, adjusting the pH value, adding into an anion exchange chromatographic column, eluting with a NaCl solution, and collecting the eluent; s5, desalting, concentrating and drying to obtain hemoglobin peptide; and S6, carrying out mass spectrometric detection, and screening bioactive peptides to obtain the oligopeptide with the activity of promoting iron absorption. The hemoglobin peptide obtained by the preparation method disclosed by the invention has relatively good iron chelation capability and iron absorption promoting capability, and the bioavailability of iron ions can be remarkably improved.

Disclosed herein are nucleic acid compositions and methods of use. The nucleic acid compositions may have a therapeutic nucleic acid sequence operably linked to a nuclear targeting sequence that increases expression of the therapeutic nucleic acid in a cell by at least 1.25 fold; at least 80% sequence identity to SEQ ID NO: 6; or a first regulatory element comprising a promoter sequence operably linked to a hemoglobin subunit gamma intron (hBGi) sequence, and a second regulatory element comprising a woodchuck hepatitis posttranscriptional regulatory element (WPRE) sequence. The nucleic acid compositions with these features may enhance therapeutic nucleic acid transfection and expression. Also disclosed herein are transgenes optimized for gene therapy applications, including novel FVIII transgene sequences, in which the B domain may be non-naturally occurring the A1 and / or A3 domain may include at least one amino acid substitution.

The utility model relates to the technical field of livestock and poultry blood utilization, in particular to a hemoglobin low-temperature extraction device which adopts two-stage separation and integrated design, is high in integration level, suitable for small-scale hemoglobin extraction work and good in practicability. Comprising a tank; the storage crushing tank is installed on the upper portion of the tank body, the liquid inlet pipe is installed on the top of the storage crushing tank, the first centrifugal separation tank is installed in the middle of the tank body, the storage crushing tank is communicated with the first centrifugal separation tank through a pipeline, and the second centrifugal separation tank is installed in the middle of the storage crushing tank through a pipeline. A residue discharging pipe is installed on the side wall of the first centrifugal separation tank, the upper end of the conveying pipe is communicated with the first centrifugal separation tank, the second centrifugal separation tank is installed on the lower portion of the tank body, a first liquid discharging pipe is installed on the side wall of the second centrifugal separation tank, and the upper end of the second liquid discharging pipe is communicated with the bottom of a second separation cavity of the second centrifugal separation tank. The upper end of the second liquid discharging pipe is located on the inner side of the inner end of the first liquid discharging pipe.

To provide a color and shape change monitoring system capable of accurately monitoring the color and shape change of a human body caused by a blood flow change.SOLUTION: The image processing apparatus includes a three dimensional point cloud data acquisition unit configured to acquire three dimensional point cloud data of a measurement target portion of a human body, a color data acquisition unit configured to acquire color data of the measurement target portion, a color-shape-data generation unit configured to generate color-shape data of the measurement target portion in which the color data is associated with the three dimensional point cloud data, and a pigment component separation unit configured to separate the color-shape data into a hemoglobin pigment component, a melanin pigment component, and a shade component.SELECTED DRAWING: Figure 1

The present application relates to a non-invasive hemoglobin detection method based on hyperspectral image reconstruction, belonging to the field of physiological signal detection. The present application irradiates human skin tissue by using a visible light source, simultaneously uses a hyperspectral camera and an RGB camera to simultaneously collect images of the irradiated skin area as a training set, trains a deep learning model, and realizes hyperspectral reconstruction of ordinary RGB images. A hemoglobin extraction feature extraction model for the visible light range diffuse reflectance spectrum is established using an algorithm, and the real hemoglobin content of the measured human body is output through a hemoglobin correction model.

The application discloses a hemoglobin camel-derived nanobody and a preparation method and application thereof. The hemoglobin camel-derived nanobody is an amino acid sequence shown in SEQ ID NO: 7, is a hemoglobin camel-derived nanobody specific to hemoglobin derived from a bactrian camel, has small molecules, can easily penetrate, has high specificity, good stability, is easy to produce and transform, has wide application prospects, and can be applied to the fields of biomedical research, clinical diagnosis and treatment and the like.

To provide dosing regimens for administering a HIF prolyl hydroxylase inhibitor in the treatment or prevention of anemia, such as anemia secondary to or associated with chronic kidney disease, or anemia associated with or resulting from chemotherapy.SOLUTION: A pharmaceutical composition in a form of a tablet or capsule comprising Compound 1 having the following structure, for use in a method of increasing hemoglobin levels in a patient in need thereof relative to a baseline hemoglobin level, wherein the patient has a hemoglobin level of ≤10.5 g / dL or ≥9.5 g / dL and ≤12 g / dL at a start of treatment, a serum hemoglobin level increases by at least about 0.1 to about 1.0 g / dL relative to the baseline hemoglobin level, and the pharmaceutical composition is used such that Compound 1 is administered to the patient once daily, for example at a dose of about 150 mg.SELECTED DRAWING: Figure 1a

A recombinant hemoglobin, a nucleic acid encoding the recombinant hemoglobin, and a preparation method therefor are provided to address the current problems of complex processes, high production costs, and low yields that exist for improving a hemoglobin having a stable tetrameric structure. The recombinant hemoglobin comprises: two or more units of recombinant hemoglobins, the units of recombinant hemoglobins each comprise four polypeptide chains, and the polypeptide chains are two α chains and two β chains. The amino acid sequences of the four polypeptide chains of each unit of recombinant hemoglobin are linked by means of intra-unit linker peptides to form the unit of recombinant hemoglobin, and two or more of the units are linked by means of inter-unit linker peptides.

Disclosed are an apparatus and method for estimating a target component value. The apparatus for estimating a target component value may include: a sensor configured to obtain a spectrum of light scattered or reflected from an object; and a processor configured to correct a first reflectance value of the spectrum based on a melanin index; obtain a second reflectance value based on the correction of the first reflectance value; convert the second reflectance value into an absorbance value; estimate the target component value based on the absorbance value; and correct the target component value based on a hemoglobin index.

The application relates to a biochemical analyzer and a detection method for detecting glycated hemoglobin. The hemoglobin concentration and the glycated hemoglobin concentration of a to-be-detected whole blood sample are obtained, and the content proportion of the glycated hemoglobin is calculated according to the hemoglobin concentration and the glycated hemoglobin concentration. The hemoglobin concentration is obtained by the following steps: obtaining a first absorbance of a to-be-detected sample liquid at a hemoglobin measurement wavelength, wherein the to-be-detected sample liquid is prepared by mixing a to-be-detected whole blood sample, a hemolytic agent and a hemoglobin detection reagent; obtaining at least two second absorbances of the to-be-detected sample liquid at at least two different correction wavelengths, wherein the correction wavelengths are designed so that the absorbance of a lipid interferent at the correction wavelength is greater than the absorbance of hemoglobin at the correction wavelength; correcting the first absorbance according to the second absorbance; and determining the hemoglobin concentration according to the corrected first absorbance. The application can improve the accuracy of hemoglobin detection.

The system comprises a laminated 5 diagnostic strip including a backing layer (105), an absorbent pad layer (106) configured for controlled capillary transport of milk, and a reagent deposit layer (107) defining multiple spatially separated dry reagent zones. The reagent zones include a pH indicator zone (101), a leukocyte esterase detection zone (102), a hemoglobin detection zone (103), and a nitrite detection zone (104), each adapted 10 for operation in the milk matrix. A calibrated sample application point (108) receives a predefined volume of untreated milk and fluidically communicates the sample to the reagent zones via the absorbent pad layer. Colorimetric reactions develop in a result window area (109), enabling simultaneous visual interpretation without analytical instruments, typically within three minutes. The invention further 15 includes a moisture-controlled storage container comprising desiccant elements (204, 205), a reference color chart (208), and a calibrated pipette (209), ensuring reagent stability and standardized use.

A blood analyzer and a hemoglobin detection method, the method comprising: a control device controls a sampling device (11) to obtain a sample to be tested (201); a control device controls a sample preparation device (12) to mix a portion of the sample to be tested with a first reagent to prepare a first sample liquid to be tested, and a control device controls a portion of the sample to be tested with a second reagent to prepare a second sample liquid to be tested (202); a control device controls a colorimetric detection device (13) to perform a hemoglobin detection on the first sample liquid to be tested using a colorimetric method to obtain a first measurement value (203); a control device controls an optical detection device (14) to perform a hemoglobin detection on the second sample liquid to be tested using a light scattering method to obtain a second measurement value (204); and a control device determines whether the sample to be tested is a sample with a falsely high hemoglobin level (205); if the sample to be tested is a sample with a falsely high hemoglobin level, the control device outputs a second measurement value (206); if the sample to be tested is a sample with a falsely high hemoglobin level, the control device outputs a first measurement value (207).

The invention relates to the technical field of biological detection, in particular to a hemoglobin content prediction method and equipment, and the method comprises the following steps: processing multiple groups of light absorption signals obtained based on a hemoglobin solution to obtain time sequence data; inputting the time sequence data into a one-dimensional convolutional neural network to extract multi-scale local features, and inputting the multi-scale local features into an attention transformation network to extract global information and local information to obtain comprehensive attention features; extracting a relationship between different peaks in the target signal corresponding to the time sequence data through a graph attention network to obtain a peak-to-peak relationship feature; and inputting the comprehensive attention features and the peak-to-peak relationship features into a feature fusion network for fusion, and calculating a hemoglobin content index based on the obtained fusion features. The method comprehensively considers the influence of the overall and local characteristics, the peak-to-peak relationship and the like, so that the hemoglobin content index can be accurately detected.

In at least one embodiment, a hemoglobin measuring device may include a plurality of sensors, a display configured to present information, and a computing device in communication with the sensors and display and having a processor and a memory storing instructions executable by the processor. The instructions may include instructions to receive, from the sensors, measurements of one or more forms of glycated hemoglobin in a blood samples, determine a total fetal hemoglobin value in the blood sample by performing a peak area summation of all forms of fetal hemoglobin, subtract the total fetal hemoglobin value from 100 to derive a total adult hemoglobin value, determine a glycated fetal hemoglobin value, compare the glycated fetal hemoglobin value to a reference range to obtain a comparison, determine a baseline glucose control value based on the comparison, and output the baseline glucose control value and the comparison to a display for medical evaluation.

The invention discloses a blood hemolysis detection kit and a detection method, and the kit comprises a hemoglobin cracking reagent which is used for destroying hemoglobin to release internal iron ions and / or ferrous ions; and the iron ion fluorescent probe is used for detecting the iron ion concentration in combination with fluorescence detection. The invention provides a strategy different from conventional hemolysis detection: the hemolysis degree is indirectly judged by detecting the content of Fe, specifically, the erythrocyte releases free hemoglobin after hemolysis, and the hemoglobin contains specific iron; based on the principle, hemoglobin is destroyed and cracked to release internal Fe and / or Fe, then a self-made iron ion fluorescent probe is adopted, and a fluorescence measurement means is combined, so that the iron ion concentration can be detected, and the hemolysis degree of the blood to be detected is judged, namely the higher the iron ion concentration is, the more serious the hemolysis is.

A stool resuspension comprising a hemoglobin stabilizing reagent is provided.SOLUTION: In some embodiments, the hemoglobin stabilizing reagent may be an osmolyte, a multivalent cation, a sugar or polysaccharide, and optionally a multivalent cation, a protoporphyrin, or an HRP stabilizing component, and optionally a multivalent cation. Also provided are methods of stabilizing hemoglobin in a stool sample in a solution, and sample collection devices comprising the solution.SELECTED DRAWING: None

The invention relates to a hemoglobin oxygen carrier based on small molecule modification as well as a preparation method and application thereof. The hemoglobin oxygen carrier comprises hemoglobin and N-fluoromethoxycarbonyl diphenylalanine, the hemoglobin forms the hemoglobin oxygen-carrying carrier through the non-covalent bond acting force between the hemoglobin and the N-fluoromethoxycarbonyl diphenylalanine. According to the hemoglobin oxygen carrier disclosed by the invention, a co-assembly strategy of N-fluoromethoxycarbonyl diphenylalanine and hemoglobin is rapidly implemented by taking a non-covalent bond acting force as a driving force. The hemoglobin oxygen-carrying carrier prepared by the process greatly shortens the stabilization time of hemoglobin molecules on the basis of ensuring the stability of molecular chemical groups, has good biocompatibility and injectable application characteristics on the basis of the characteristics of non-covalent acting force, and provides a new foundation for research and development of a new generation of hemoglobin oxygen-carrying carriers. And an engineering design thought and a theoretical basis are provided.

To provide a method for increasing a shelf-life of a preserved red blood cell composition for drug delivery.SOLUTION: Provided is a method for increasing the shelf-life of a preserved red blood cell composition for drug delivery, comprising: obtaining a red blood cell comprising a pharmaceutical agent; treating the red blood cell comprising the pharmaceutical agent with a chemical agent to prepare a red blood cell comprising a hemoglobin derivative; and storing the red blood cell comprising the hemoglobin derivative under a storage atmosphere comprising an oxygen pressure of less than 20 millimeters of mercury (mmHg) to prepare a preserved red blood cell composition for drug delivery.SELECTED DRAWING: Figure 1

The invention provides a hemolysis index quality control product as well as a preparation method and application thereof. The hemolysis index quality control product provided by the invention comprises serum, a preservative and a hemolysis component, the serum, the preservative and the hemolysis component are mixed in advance according to different preset proportions to obtain quality control products with different hemolysis indexes; the hemolysis component is a blood sample with damaged red blood cells or a hemoglobin standard substance; the preservative is 0.05% of sodium azide. The hemolysis index quality control product provided by the invention can be used for monitoring the reaction and detection capability of a clinical laboratory inspection instrument on a hemolysis sample, and can also be used for assisting biochemical detection, analysis and judgment.

The application discloses a hemoglobin mutant with improved stability and application thereof, and belongs to the technical field of genetic engineering. The application lays a foundation for obtaining an ideal stable human hemoglobin mutant by designing a high-throughput screening method for the structural stability of human hemoglobin and the hematin binding intensification mutant. The application determines hot amino acid sites for the structural stability and thermal stability modification of human hemoglobin through semi-rational design, and further carries out iterative saturation mutation to obtain an ideal mutant rHb 9th The application has the advantages that in terms of structural stability, thermal stability, anti-autoxidation capacity, hematin binding rate, anti-hematin loss rate and human hemoglobin yield, etc. wild‑type The application has the advantages that in terms of structural stability, thermal stability, anti-autoxidation capacity, hematin binding rate, anti-hematin loss rate and human hemoglobin yield, etc.

This application relates to the field of medical image processing technology, specifically to a hemoglobin emphasis device and method for endoscopes. The device includes a light source unit; an imaging unit for acquiring reflected light signals from a target area under multispectral illumination and outputting a raw Bayer format image or an RGB color image; and an image processing unit for receiving and processing the output Bayer format image or RGB color image, comprising at least: a spectral reconstruction module for calculating and reconstructing a single-band image signal using a spectral reconstruction model; a hemoglobin concentration calculation module configured to calculate a relative hemoglobin concentration based on the image signal; and an image enhancement module configured to perform pixel-level gain adjustment on the raw color image or the processed image, convert it to a set color space for contrast mapping, and finally output a hemoglobin-emphasized image. The image output by this invention can significantly improve the contrast between blood vessels and surrounding tissues.

Apparatus and methods for a blood sample (48, 50) are described that include measuring a hemoglobin concentration of at least a portion (48) of the blood sample by performing a first measurement on the blood sample. The mean corpuscular hemoglobin of the blood sample (48, 50) is measured by performing a second measurement on the blood sample (48, 50). A parameter of the blood sample is determined based on a relationship between the hemoglobin concentration and the mean corpuscular hemoglobin. Other applications are described.

Disclosed herein are nucleic acid compositions and methods of use. The nucleic acid compositions may have a therapeutic nucleic acid sequence operably linked to a nuclear targeting sequence that increases expression of the therapeutic nucleic acid in a cell by at least 1.25 fold; at least 80% sequence identity to SEQ ID NO: 6; or a first regulatory element comprising a promoter sequence operably linked to a hemoglobin subunit gamma intron (hBGi) sequence, and a second regulatory element comprising a woodchuck hepatitis posttranscriptional regulatory element (WPRE) sequence. The nucleic acid compositions with these features may enhance therapeutic nucleic acid transfection and expression. Also disclosed herein are transgenes optimized for gene therapy applications, including novel FVIII transgene sequences, in which the B domain may be non-naturally occurring the A1 and / or A3 domain may include at least one amino acid substitution.

A method for immunological detection of hemoglobin, the method comprising a step for performing immunological detection using an anti-hemoglobin antibody in the presence of hemoglobin and haptoglobin, the haptoglobin having the following characteristics (1): (1) at least a portion of an N-linked sugar chain is deleted. The present invention further provides a method for suppressing fluctuations in the detection value of hemoglobin, a method and a solution for stabilizing hemoglobin, a kit for detecting hemoglobin, and the haptoglobin and a method for producing the haptoglobin. According to the present invention, it is possible to detect hemoglobin by suppressing fluctuations in the detection value of hemoglobin due to haptoglobin.

An object of the present invention is to provide an eluent for suppressing bimodality of hemoglobin F which is a β - thalassemia disease marker in hemoglobin analysis in cation exchange chromatography and stably separating hemoglobin F without depending on the type of diluent, and a method for separating hemoglobin F and a method for diagnosing hemoglobin F using the eluent.SOLUTION: In the analysis of a hemoglobin sample using cation exchange chromatography, the problem is solved by an eluent having a pH of 5.0 to 6.0, which is passed when separating and quantifying hemoglobin F from the hemoglobin sample, wherein the eluent contains at least one or more pH buffers, and a relationship between the pH of the eluent and a pKa value in a range of 5.0 to 7.0 among pKa values indicated by the pH buffers is a relationship of pH ≤ pKa ≤ pH + 1.0.SELECTED DRAWING: Figure 1

The invention provides a color correction method and apparatus, an electronic device and a computer readable storage medium. The method comprises the steps of obtaining a target face image; determining a melanin dominant component and a hemoglobin dominant component in the target face image; determining a skin color type corresponding to the target face image according to the melanin dominant component and the hemoglobin dominant component; determining a correction parameter corresponding to the skin color type; correcting a preset color correction matrix through the correction parameter to obtain a target color correction matrix; and correcting the target face image through the target color correction matrix. The melanin dominant component and the hemoglobin dominant component in the target face image are determined, so that the skin color features of the user in the target face image are determined, the specific skin color type is determined, the color correction matrix is adjusted according to the skin color type, and then correction is performed through the target color correction matrix, so that the color correction accuracy is improved. And different skin color types can be adapted.